Anti‐angiogenic properties of a sulindac analogue

Background and purpose:

Angiopoietins (Ang) are crucial for new blood vessel formation and exert their effects by acting on the Tie2 receptor. We have recently described a sulindac analogue 2‐((1E,Z)‐1‐benzylidene‐5‐bromo‐2‐methyl‐1H‐inden‐3‐yl)acetic acid; termed C‐18 from now onwards) that inhibits Tie2 receptor activity in kinase assays in vitro. Here, we have assessed the ability of C‐18 to inhibit angiogenesis‐related properties of endothelial cells and tested its selectivity for the Tie2 receptor.

Experimental approach:

For in vitro experiments human umbilical vein endothelial cells (HUVEC) were used. Proliferation was measured using the MTT assay; migration assays were performed in a modified Boyden chamber and tube‐like structure formation was determined on matrigel. The effects of C‐18 in vivo were evaluated in the chicken chorioallantoic membrane (CAM).

Key results:

Pre‐treatment of HUVEC with C‐18 blocked Ang‐1‐stimulated migration, but also abolished vascular endothelial cell growth factor (VEGF)‐ and fibroblast growth factor 2‐induced responses. Incubation with C‐18 inhibited serum‐induced proliferation in a concentration‐dependent manner; C‐18 was, however, without effect on Ang‐1‐induced survival. In addition, we observed that C‐18 did not inhibit ligand‐induced receptor phosphorylation of Tie2 or VEGFR2. On the other hand, C‐18 blocked activation of members of the mitogen‐activated protein kinase family and of the Ser/Thr kinase Akt induced by both VEGF and Ang‐1. Furthermore, incubation of CAMs with C‐18 led to a dose‐dependent inhibition of vascular length.

Conclusions and implications:

C‐18 did not act as a Tie2 inhibitor, as originally thought, but rather inhibited growth factor‐stimulated signalling pathways that regulate endothelial cell migration and potently reduces neovascularization in vivo.

DOI: 10.1038/sj.bjp.0707534

View this article

• Full article (html)
• Enhanced article (html)
• PDF
• References